Information
-
Patent Application
-
20040097535
-
Publication Number
20040097535
-
Date Filed
March 13, 200322 years ago
-
Date Published
May 20, 200420 years ago
-
CPC
-
US Classifications
-
International Classifications
- A61K031/4745
- A61K031/407
- C07D471/14
- C07D471/02
- A61K031/403
Abstract
There are described tetrahydrocarbazoles of formula (1) or (2). The compounds are suitable as antimicrobial active ingredients.
Description
[0001] The present invention relates to novel tetrahydrocarbazoles, to a process for the preparation of those compounds and to the use thereof as antimicrobial active ingredients.
[0002] The tetrahydrocarbazoles according to the invention correspond to formula
1
[0003] wherein
[0004] R1 is hydrogen; C1-C20alkyl; C3-C12cycloalkyl; C2-C20alkenyl; C4-C12cycloalkenyl; C3-C20-alkynyl; C4-C12cycloalkynyl; phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C5alkyl, C3-C12cycloalkyl, C1-C5alkoxy, C3-C12cycloalkoxy, halogen, carboxy, C1-C7alkylcarbonyl, C1-C7alkoxycarbonyl, C3-C12cycloalkylcarbonyl, C3-C12-cycloalkoxycarbonyl, cyano, trifluoromethyl, pentafluoroethyl, amino, N,N-mono- or di-C1-C20alkylamino or by nitro,
[0005] R2 is hydrogen; hydroxy; C1-C20alkyl; C3-C12cycloalkyl; C1-C20hydroxyalkyl; C1-C20-hydroxyalkoxy; C1-C20aminoalkyl; N—C1-C20monoalkylamino-C1-C20alkyl; N—C1-C20-monoalkylaminohydroxy-C1-C20alkoxy; N,N—C1-C20dialkylamino-C1-C20alkyl; N,N—C1-C20dialkylaminohydroxy-C1-C20alkoxy; carboxy; carboxy-C1-C20alkyl ester, C1-C20-haloalkyl; C1-C20haloalkoxy; C2-C20alkenyl; C4-C12cycloalkenyl; C3-C20alkynyl; C4-C12-cycloalkynyl; C1-C20alkoxy; C2-C20alkenyloxy; C2-C20alkynyloxy; halogen; cyano; C1-C7alkylcarbonyl; nitro; trifluoromethyl; or pentafluoroethyl;
[0006] R3 and R4 are each independently of the other hydrogen; or C1-C20alkyl; or R3 and R4 together denote a C2-C20alkylene radical; a C2-C20alkenylene radical; a C4-C20-alkynylene radical; or a C3-C20alkylene radical interrupted by —N(R6)—, it being possible for such bivalent radicals to be further substituted by one or more C1-C20alkyl, C3-C12-cycloalkyl, C2-C20alkenyl, C4-C12cycloalkenyl, C3-C20alkynyl, C4-C12cycloalkynyl, C1-C7alkoxycarbonyl, or phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C5alkyl, C3-C12cycloalkyl, C1-C5alkoxy, C3-C12cycloalkoxy, halogen, carboxy, C1-C7alkoxycarbonyl, C3-C12cycloalkoxycarbonyl, cyano, trifluoromethyl, pentafluoroethyl, amino, N,N-mono- or di-C1-C20alkylamino or by nitro; or R3 and R4 together denote a bicyclo[x.y.z.]C4-C20alkylene; or bicyclo[x.y.z.]C4-C20alkylene interrupted by —N(R6)—, wherein x, y and z are each independently of the others from 0 to 10;
[0007] R5 is hydrogen; hydroxy; C1-C20alkyl; C1-C20alkoxy; C3-C12cycloalkyl; C2-C20alkenyl C4-C12cycloalkenyl; C3-C20alkynyl; C4-C12cycloalkynyl; phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C5alkyl, C3-C12cycloalkyl, C1-C5alkoxy, C3-C12-cyclolkoxy, halogen, carboxy, C1-C7alkoxycarbonyl, C3-C12cycloalkoxycarbonyl, cyano, triluoroethyl, pentafluoroethyl, amino, N,N-mono- or di-C1-C20alkylamino or by nitro;
[0008] R6 is hydrogen; C1-C20alkyl; C3-C12cycloalkyl; C2-C20alkenyl; C4-C12cycloalkenyl; C3-C20-alkynyl; C4-C12cycloalkynyl; C1-C7alkoxycarbonyl; phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C5alkyl, C3-C12cycloalkyl, C1-C5alkoxy, C3-C12-cyclolkoxy, halogen, carboxy, C1-C7alkoxycarbonyl, C3-C12cycloalkoxycarbonyl, cyano, trifluoromethyl, pentafluoroethyl, amino, N,N-mono- or di-C1-C20alkylamino or by nitro;
[0009] Q is —SO2—; —O—; or —(CO)—;
[0010] X is —CH—; or —N—;
[0011] m is from 1 to 3; and
[0012] t is 0 or 1.
[0013] C1-C20Alkyl denotes straight-chain or branched alkyl radicals, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, amyl, isoamyl or tert-amyl, heptyl, octyl, isooctyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl or eicosyl.
[0014] C3-C12Cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclodocecyl and especially cyclohexyl.
[0015] Within the scope of the meanings given, alkenyl includes inter alia allyl, isopropenyl, 2-butenyl, 3-butenyl, isobutenyl, n-penta-2,4dienyl, 3-methylbut-2-enyl, n-oct-2-enyl, n-dodec-2-enyl, isododecenyl, n-dodec-2-enyl or n-octadec-4-enyl.
[0016] C1-C20Alkoxy denotes straight-chain or branched radicals, such as methoxy, ethoxy, propoxy, butoxy or pentyloxy, hexyloxy, heptyloxy, octyloxy, isooctyloxy, nonyloxy, decyloxy, undecyloxy, dodecyloxy, tetradecyloxy, pentadecyloxy, hexadecyloxy, heptadecyloxy, octadecyloxy or eicosyloxy.
[0017] Halogen is fluorine, chlorine, bromine or iodine.
[0018] Preference is given to the use of compounds of formula (1) or (2) wherein
[0019] R1 is hydrogen; C1-C20alkyl; C3-C12cycloalkyl; C2-C20alkenyl; C4-C12cycloalkenyl; C3-C20alkynyl; C4-C12cycloalkynyl; phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C5alkyl, C3-C12cycloalkyl, C1-C5alkoxy, C3-C12cycloalkoxy, halogen, carboxy, C1-C7alkylcarbonyl, C1-C7alkoxycarbonyl, C3-C12cycloalkylcarbonyl, C3-C12-cycloalkoxyarbonyl, cyano, trifluoromethyl, pentafluoroethyl, amino, N,N-mono- or di-C1-C20alkylmino or by nitro,
[0020] R2 is hydrogen; hydroxy; C1-C20alkyl; C3-C12cycloalkyl; C2-C20alkenyl; C4-C12cycloalkenyl; C3-C20alkynyl; C4-C12cycloalkynyl; C1-C20alkoxy; C2-C20alkenyloxy; C2-C20alkynyloxy; halo cyano; C1-C7alkylcarbonyl; nitro; trifluoromethyl; or pentafluoroethyl;
[0021] R3 and R4 are each independently of the other hydrogen; or C1-C20alkyl; or R3 and R4 denote a C2-C20alkylene radical; a C2-C20alkenylene radical; a C4-C20alkynylene radical; or a C3-C20alkylene radical interrupted by —N(R6)—, it being possible for such bivalent radicals to be further substituted by one or more C1-C20alkyl, C3-C12cycloalkyl, C2-C20-alkenyl, C4-C12cycloalkenyl, C3-C20alkynyl, C4-C12cycloalkynyl, C1-C7alkoxycarbonyl, or phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C5alkyl, C3-C12-cycloalkyl, C1-C5alkoxy, C3-C12cycloalkoxy, halogen, carboxy, C1-C7alkoxycarbonyl, C3-C12cycloalkoxycarbonyl, cyano, trifluoromethyl, pentafluoroethyl, amino, N,N-mono- or di-C1-C20alkylamino or by nitro;
[0022] R5 is hydrogen; hydroxy; C1-C20alkyl; C1-C20alkoxy; C3-C12cycloalkyl; C2-C20alkenyl; C4-C12cycloalkenyl; C3-C20alkynyl; C4-C12cycloalkynyl; phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C5alkyl, C3-C12cycloalkyl, C1-C5alkoxy, C3-C12-cycloalkoxy, halogen, carboxy, C1-C7alkoxycarbonyl, C3-C12cycloalkoxycarbonyl, cyano, trifluoromethyl, pentafluoroethyl, amino, N,N-mono- or di-C1-C20alkylamino or by nitro;
[0023] R6 is hydrogen; C1-C20alkyl; C3-C12cycloalkyl; C2-C20alkenyl; C4-C12cycloalkenyl; alkynyl; C4-C12cycloalkynyl; C1-C7alkoxycarbonyl; phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C5alkyl, C3-C12cycloalkyl, C1-C5alkoxy, C3-C12-cycloalkoxy, halogen, carboxy, C1-C7alkoxycarbonyl, C3-C12cycloalkoxycarbonyl, cyano, trifluorom thyl, pentafluoroethyl, amino, N,N-mono- or di-C1-C20alkylamino or by nitro;
[0024] Q is —SO2—; —O—; or —(CO)—;
[0025] X is —CH—; or —N—;
[0026] m is from 1 to 3; and
[0027] t is 0 or 1.
[0028] In formula (1)
[0029] R1 is preferably hydrogen; C1-C20alkyl; phenyl or phenyl-C1-C5alkyl, and is especially hydrogen; or C1-C5alkyl.
[0030] Preference is given also to compounds of formula (1) wherein
[0031] R2 is hydrogen; C1-C20alkyl; C1-C20alkoxy; or halogen and is especially hydrogen; C1-C5alkyl; C1-C5alkoxy; or halogen.
[0032] Very special preference is given to compounds of formula
2
[0033] wherein
[0034] R1 is hydrogen; C1-C20alkyl; C3-C12cycloalkyl; C2-C20alkenyl; C4-C12cycloalkenyl; C3-C20-alkynyl; C4-C12cycloalkynyl; phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C5alkyl, C3-C12cycloalkyl, C1-C5alkoxy, C3-C12cycloalkoxy, halogen, carboxy, C1-C7alkylcarbonyl, C1-C7alkoxycarbonyl, C3-C12cycloalkylcarbonyl, C3-C12-cycloalkoxyarbonyl, cyano, trifluoromethyl, pentafluoroethyl, amino, N,N-mono- or di-C1-C20alkylmino or by nitro,
[0035] R2 is hydrogen; hydroxy; C1-C20alkyl; C3-C12cycloalkyl; C2-C20alkenyl; C4-C12cycloalkenyl; C3-C20alkynyl; C4-C12cycloalkynyl; C1-C20alkoxy; C2-C20alkenyloxy; C2-C20alkynyloxy; halogen; cyano; C1-C7alkylcarbonyl; nitro; trifluoromethyl; or pentafluoroethyl;
[0036] R5 is hydrogen; hydroxy; C1-C20alkyl; C1-C20alkoxy; C3-C12cycloalkyl; C2-C20alkenyl; C4-C12cycloalkenyl; C3-C20alkynyl; C4-C12cycloalkynyl; phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C5alkyl, C3-C12cycloalkyl, C1-C5alkoxy, C3-C12-cycloalkoxy, halogen, carboxy, C1-C7alkoxycarbonyl, C3-C12cycloalkoxycarbonyl, cyano, trifluoromethyl, pentafluoroethyl, amino, N,N-mono- or di-C1-C20alkylamino or by nitro;
[0037] R6 is hydrogen; C1-C20alkyl; C3-C12cycloalkyl; C2-C20alkenyl; C4-C12cycloalkeny alkynyl; C4-C12cycloalkynyl; C1-C7alkoxycarbonyl; phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C7alkyl, C3-C12cycloalkyl, C1-C5alkoxy, C3-C12-cycloalkoxy, halogen, carboxy, C1-C7alkoxycarbonyl, C3-C12cycloalkoxycarbonyl, cyano, trifluoromethyl, pentafluoroethyl, amino, N,N-mono- or di-C1-C20alkylamino or by nitro;
[0038] Q is —SO2—; —O—; or —(CO)—;
[0039] T1 is C2-C20calkylene; C2-C20alkenylene; C4-C20alkynylene; or C3-C20alkylene interrupted by
3
[0040] X is —CH—; or —N—;
[0041] s is from 1 to 4; and
[0042] t is 0 or 1.
[0043] Preference is given to compounds of formula (3) or (4) wherein
[0044] T1 is a —(CH2)2-12— radical and
[0045] R6 is hydrogen; or C1-C5alkyl,
[0046] and especially to compounds of formula (3) or (4) wherein
[0047] T1 is a —(CH2)3—, —(CH2)4—, —(CH2)5—, or —(CH2)10— radical; and
[0048] R6 is hydrogen; or C1-C5alkyl.
[0049] R5 in formula (1) is preferably hydrogen; C1-C20alkyl; phenyl or phenyl-C1-C5alkyl; and more especially hydrogen; C1-C5alkyl; or phenyl.
[0050] More especially preferred compounds according to the invention correspond to formula
4
[0051] wherein
[0052] R6′ and R6″ are each independently of the other hydrogen; C1-C20alkyl; C1-C7alkoxy-carbonyl; phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C5alkyl, C1-C7alkoxycarbonyl, N,N-mono- or di-C1-C20alkylamino or by nitro;
[0053] T1 is
5
[0054] and
[0055] R1, R2, R5, R6 and X are as defined for formula (3).
[0056] In formulae (5) and (6) preferably
[0057] R6′, R6″ and R6 are each independently of the others hydrogen; C1-C20alkyl; C1-C7-alkoxycarbonyl; phenyl; or phenyl-C1-C5alkyl.
[0058] Special preference is given to compounds of formula (5) and (6) wherein R6′ and R6″ and R6 are each independently of the others hydrogen; C1-C5alkyl; C1-C7 alkoxycarbonyl; phenyl or benzyl.
[0059] Further preferred compounds according to the invention correspond to formula
6
[0060] wherein
[0061] R1 is hydrogen; or C1-C5alkyl;
[0062] R2 is hydrogen; C1-C4alkyl; Cl or Br,
[0063] R5 is hydrogen; C1-C5alkyl; or phenyl
[0064] R6′ and R6″ are each independently of the other hydrogen, C1-C5alkyl; or C1-C7alkoxy-carbonyl;
[0065] R6 is hydrogen; C1-C5alkyl; C1-C7alkylcarbonyl; or phenyl-C1-C5alkyl;
[0066] T1 is
7
[0067] and
[0068] X is —CH—.
[0069] Compounds according to the invention are listed in Tables 1 a and b below by way of example:
1TABLE 1a
|
|
General structural formula
|
89
|
Compound of formulaR1R210R5Yield [surfaces %]
|
9HH—(CH2)4—Ph92
10H7-Br—(CH2)4—Ph75
11MeH—(CH2)4—Ph68
12HH—(CH2)3—Ph93
|
13HH11Ph67
|
14HH—(CH2)5—Ph92
|
15HH12Ph79
|
16HH—(CH2)4—H48
17HH—(CH2)4—Et55
18H7-Br—(CH2)3—Ph96
|
19H7-Br13Ph83
|
20H7-Br—(CH2)5—Ph68
21MeH—(CH2)3—Ph95
|
22MeH14Ph64
|
23MeH—(CH2)5—Ph75
|
24MeH15Ph38
|
25HH—(CH2)3—H86
|
26HH16H95
|
27HH—(CH2)5—H68
|
28HH17H88
|
29H7-Br—(CH2)4—H92
|
30H7-Br—(CH2)3—H90
|
31H7-Br18H41
|
32H7-Br—(CH2)5—H79
|
33H7-Br19H44
|
34MeH—(CH2)4—H77
35MeH—(CH2)3—H95
|
36MeH20H84
|
37MeH—(CH2)5—H87
38HH—(CH2)3—Et91
|
39HH21Et66
|
40HH—(CH2)5—Et89
|
41HH22Et57
|
42H7-Br—(CH2)4—Et85
43H7-Br—(CH2)3—Et90
|
44H7-Br23Et47
|
45H7-Br—(CH2)5—Et51
|
46H7-Br24Et91
|
47MeH—(CH2)4—Et94
48MeH—(CH2)3—Et95
|
49MeH25Et80
|
50MeH—(CH2)5—Et90
51H9-Et—(CH2)4—Ph95
|
52HH26Ph96
|
53HHisopropylPh59
|
54HH27H19
|
55HH28H85
|
56HH29H44
|
57HH30H65
|
58HH31H62
|
59HH32H49
|
60HH33H37
|
61HH—(CH2)10—H90
62HH—(CH2)6—H63
|
63HH34H81
|
64HHisopropylH28
65HHMeH62
66HHEtH58
|
67HH35H58
|
68H7-Br36H93
|
69H7-Br37H93
|
70H7-Br38H90
|
71H7-Br39H93
|
72H7-Br40H94
|
73H7-Br—(CH2)6—H33
74H9-Et—(CH2)4—H68
75H9-Et—(CH2)3—H91
|
76H9-Et41H99
|
77H9-Et—(CH2)5—H93
|
78H9-Et42H82
|
79H9-Et43H56
|
80H9-Et44H78
|
81H9-Et45H36
|
82H9-Et46H63
|
83H9-Et47H74
|
84H9-Et48H91
|
85H9-Et49H64
|
86H9-Et50H39
|
87H9-Et51H26
|
88H9-Et—(CH2)10—H64
89H9-Et—(CH2)6—H86
|
90H9-Et52H63
|
91H7-MeO—(CH2)4—H93
92H7-MeO—(CH2)3—H93
|
93H7-MeO53H56
|
94H7-MeO—(CH2)5—H71
|
95H7-MeO54H10
|
96H7-MeO55H88
|
97H7-MeO56H22
|
98H7-MeO57H76
|
99H7-MeO58H60
|
100H7-MeO59H83
|
101H7-MeO60H94
|
102H7-MeO61H79
|
103H7-MeO62H74
|
104H7-MeO63H84
|
105H7-MeO64H80
|
106H7-MeO—(CH2)10—H93
107H7-MeO—(CH2)6—H34
|
108H7-MeO65H27
|
109HH—(CH2)4—Me54
110HH—(CH2)3—Me81
|
111HH66Me98
|
112HH—(CH2)5—Me93
|
113HH67Me47
|
114HH68Me86
|
115HH69Me16
|
116HH70Me64
|
117HH71Me98
|
118HH72Me87
|
119HH73Me98
|
120HH74Me98
|
121HH75Me83
|
122HH76Me93
|
123HH77Me89
|
124HH—(CH2)10—Me95
125HH—(CH2)6—Me43
|
126HH78Me98
|
127H7-Br—(CH2)4—Me92
128H7-Br—(CH2)3—Me94
|
129H7-Br79Me99
|
130H7-Br—(CH2)5—Me76
|
131H7-Br80Me69
|
132H7-Br81Me97
|
133H7-Br82Me22
|
134H7-Br83Me92
|
135H7-Br84Me95
|
136H7-Br85Me69
|
137H7-Br86Me84
|
138H7-Br87Me75
|
139H7-Br88Me87
|
140H7-Br89Me16
|
141H7-Br90Me73
|
142H7-Br—(CH2)10—Me81
143H7-Br—(CH2)6—Me97
|
144H7-Br91Me92
|
145H9-Et—(CH2)4—Me97
146H9-Et—(CH2)3—Me97
|
147H9-Et92Me46
|
148H9-Et—(CH2)5—Me88
|
149H9-Et93Me5
|
150H9-Et94Me32
|
151H9-Et95Me31
|
152H9-Et96Me85
|
153H9-Et97Me87
|
154H9-Et98Me92
|
155H9-Et99Me93
|
156H9-EtMe27
|
157H9-Et100Me73
|
158H9-Et101Me79
|
159H9-Et102Me13
|
160H9-Et103Me81
|
161H9-Et—(CH2)10—Me98
162H9-Et—(CH2)6—Me97
|
163H9-Et104Me55
|
164H7-MeO—(CH2)4—Me58
165H7-MeO—(CH2)3—Me54
|
166H7-MeO105Me93
|
167H7-MeO—(CH2)5—Me96
|
168H7-MeO106Me7
|
169H7-MeO107Me82
|
170H7-MeO108Me36
|
171H7-MeO109Me71
|
172H7-MeO110Me29
|
173H7-MeO111Me80
|
174H7-MeO112Me68
|
175H7-MeO113Me95
|
176H7-MeO114Me79
|
177H7-MeO115Me89
|
178H7-MeO116Me72
|
179H7-MeO—(CH2)10—Me73
180H7-MeO—(CH2)6—Me27
|
181H7-MeO117Me95
|
[0070]
2
TABLE 1b
|
|
|
General structural formula
|
|
118
119
|
|
|
Compound of formula
R1
R2
R2′
120
R4
Yield [surfaces %]
|
|
|
182
—H
—H
—H
121
—H
89
|
|
183
—H
—H
—H
122
—H
56
|
|
184
—H
—H
—H
123
—H
95
|
|
185
—H
—H
—H
—(CH2)13—
—H
82
|
186
—H
6-Me
—H
124
—H
93
|
|
187
—H
6-OMe
—H
—(CH2)5—
—H
90
|
188
—H
6-OMe
—H
—(CH2)10—
—H
50
|
189
—H
125
—H
—(CH2)5—
—H
85
|
|
190
—H
126
—H
127
—H
40
|
|
191
—H
7-F
—H
—(CH2)5—
—H
88
|
192
—H
7-F
—H
—(CH2)10—
—H
93
|
193
—H
7-F
—H
128
—H
94
|
|
194
—H
7-Me
—H
—(CH2)5—
—H
81
|
195
—H
7-Me
—H
—(CH2)10—
—H
96
|
196
—H
8-Cl
—H
—(CH2)6—
—H
87
|
197
—H
8-Cl
—H
—(CH2)10—
—H
44
|
198
—H
8-Cl
—H
—(CH2)2—
—H
97
|
199
—H
8-Cl
—H
129
—H
99
|
|
200
—H
6-COOMe
—H
—(CH2)2—
—H
66
|
201
—H
6-COOMe
—H
130
—H
82
|
|
202
—H
8-Me
—H
—(CH2)5—
—H
76
|
203
—H
8-Me
—H
131
—H
82
|
|
204
—H
8-F
—H
—(CH2)5—
—H
76
|
205
—H
8-F
—H
—(CH2)10—
—H
56
|
206
—H
8-F
—H
—(CH2)2—
—H
75
|
207
—H
8-F
—H
132
—H
90
|
|
208
—H
9-F
—H
—(CH2)5—
—H
93
|
209
—H
9-F
—H
—(CH2)10—
—H
30
|
210
—H
9-F
—H
—(CH2)2—
—H
89
|
211
—H
9-F
—H
133
—H
99
|
|
212
—H
8-CF3
—H
—(CH2)5—
—H
42
|
213
—H
8-CF3
—H
—(CH2)10—
—H
40
|
214
—H
8-CF3
—H
—(CH2)2—
—H
61
|
215
—H
8-CF3
—H
134
—H
71
|
|
216
—H
7-F
8-F
—(CH2)5—
—H
68
|
217
—H
7-F
8-F
—(CH2)10—
—H
90
|
218
—H
7-F
8-F
—(CH2)2—
—H
87
|
219
—H
7-F
8-F
135
—H
98
|
|
220
—H
9-Me
—H
—(CH2)5—
—H
95
|
221
—H
9-Me
—H
—(CH2)10—
—H
97
|
222
—H
9-Me
—H
136
—H
75
|
|
223
—H
6-Cl
—H
—(CH2)2—
—H
95
|
224
—H
6-Cl
—H
137
—H
91
|
|
225
—H
6-F
—H
—(CH2)2—
—H
94
|
226
—H
6-F
—H
138
—H
97
|
|
227
—H
9-OMe
—H
—(CH2)5—
—H
93
|
228
—H
9-OMe
—H
—(CH2)10—
—H
90
|
229
—H
9-OMe
—H
139
—H
98
|
|
230
—H
8-OMe
—H
—(CH2)5—
—H
84
|
231
—H
8-OMe
—H
140
—H
96
|
|
232
—H
7-COOMe
—H
—(CH2)5—
—H
87
|
233
—H
7-COOMe
—H
—(CH2)10—
—H
83
|
234
—H
7-COOMe
—H
—(CH2)2—
—H
54
|
235
—H
7-COOMe
—H
141
—H
57
|
|
236
—H
7-OMe
8-OMe
—(CH2)5—
—H
99
|
237
—H
7-OMe
8-OMe
—(CH2)10—
—H
69
|
238
—H
7-OMe
8-OMe
142
—H
58
|
|
[0071] The preparation of the tetrahydrocarbazoles according to the invention is carried out according to widely known methods in a 3-component reaction, as described in the publication by W. Noland et al., J. Heterocycl. Chem., 1993, 30, 81-91.
[0072] For that purpose, mixtures of a (substituted) indole, ketone or aldehyde and a dienophile are reacted in a suitable solvent, e.g. 1-butanol, toluene, DMF, DMSO or Tetralin, using acid catalysts, e.g. hydrochloric acid, trifluoroacetic acid, toluenesulfonic acid, etc. The ketone or aldehyde component can also serve as solvent. The mixture is heated for several hours at a temperature of from 50° C. to 140° C. The resulting tetrahydrocarbazoles are filtered off and washed, or precipitated from the solvent with cold n-hexane and filtered off. Some of the substances are also obtained by concentrating the reaction mixture by evaporation.
[0073] The course of the reaction can be represented schematically as follows:
143
[0074] The tetrahydrocarbazoles obtained in that manner are generally obtained in the form of race-mates and are mainly in the cis stereochemical form. Some compounds also form trans stereochemical isomers.
[0075] The invention relates also to the process for the preparation of those compounds.
[0076] The tetrahydrocarbazoles according to the invention exhibit pronounced antimicrobial activity, especially against pathogenic gram-positive and gram-negative bacteria and against bacteria of the skin flora, and also against yeasts and moulds. They are accordingly especially suitable for disinfection, deodorisation, and for the general and antimicrobial treatment of the skin and mucosa, and integumentary appendages (hair), especially for the disinfection of hands and wounds.
[0077] The compounds are accordingly suitable as antimicrobial active ingredients and as preservatives in personal care preparations, such as shampoos, bath additives, hair care products, liquid and solid soaps (based on synthetic surfactants and salts of saturated and/or unsaturated fatty acids), lotions and creams, deodorants, other aqueous or alcoholic solutions, e.g. cleansing solutions for the skin, moist wipes, oils or powders.
[0078] The invention accordingly relates also to a personal care preparation comprising at least one compound of formula (1) or (2) and cosmetically tolerable carriers or adjuvants.
[0079] The personal care preparation according to the invention contains from 0.01 to 15% by weight, preferably from 0.1 to 10% by weight, based on the total weight of the composition, of a compound of formula (1) or (2) and cosmetically tolerable adjuvants.
[0080] Depending upon the form of the personal care preparation, it comprises, in addition to the compound of formula (1) or (2), further constituents, such as sequestering agents, colourings, perfume oils, thickening or solidifying agents (consistency regulators), emollients, UV-absorbers, skin protective agents, antioxidants, additives that improve the mechanical properties, such as dicarboxylic acids and/or aluminium, zinc, calcium or magnesium salts of C14-C22 fatty acids and, optionally, preservatives.
[0081] The personal care preparation according to the invention may be in the form of a water-in-oil or oil-in-water emulsion, an alcoholic or alcohol-containing formulation, a vesicular dispersion of an ionic or non-ionic amphiphilic lipid, a gel, a solid stick or an aerosol formulation.
[0082] As a water-in-oil or oil-in-water emulsion the cosmetically tolerable adjuvant contains preferably from 5 to 50% of an oil phase, from 5 to 20% of an emulsifier and from 30 to 90% water. The oil phase may comprise any oil suitable for cosmetic formulations, for example one or more hydrocarbon oils, a wax, a natural oil, a silicone oil, a fatty acid ester or a fatty alcohol.
[0083] Preferred mono- or poly-ols are ethanol, isopropanol, propylene glycol, hexylene glycol, glycerol and sorbitol.
[0084] Cosmetic formulations according to the invention are used in various fields. There come into consideration, for example, especially the following preparations:
[0085] skin-care preparations, e.g. skin-washing and cleansing preparations in the form of tablet-form or liquid soaps, synthetic detergents or washing pastes,
[0086] bath preparations, e.g. liquid (foam baths, milks, shower preparations) or solid bath preparations, e.g. bath cubes and bath salts;
[0087] skin-care preparations, e.g. skin emulsions, multi-emulsions or skin oils;
[0088] cosmetic personal care preparations, e.g. facial make-up in the form of day creams or powder creams, face powder (loose or compressed), rouge or cream make-up, eyecare preparations, e.g. eyeshadow preparations, mascara, eyeliner, eyecreams or eye-fix creams; lip-care preparations, e.g. lipsticks, lip gloss, lip contour pencils, nail-care preparations, such as nail varnish, nail varnish removers, nail hardeners or cuticle removers;
[0089] intimate hygiene preparations, e.g. intimate washing lotions or intimate sprays;
[0090] foot-care preparations, e.g. foot baths, foot powders, foot creams or foot balsams, special deodorants and antiperspirants or callus-removing preparations;
[0091] light-protective preparations, such as sun milks, lotions, creams, oils, sun-blocks or tropicals, pre-tanning preparations or after-sun preparations;
[0092] skin-tanning preparations, e.g. self-tanning creams;
[0093] depigmenting preparations, e.g. preparations for bleaching the skin or skin-lightening preparations;
[0094] insect repellents, e.g. insect-repellent oils, lotions, sprays or sticks;
[0095] deodorants, such as deodorant sprays, pump-action sprays, deodorant gels, sticks or roll-ons;
[0096] antiperspirants, e.g. antiperspirant sticks, creams or roll-ons;
[0097] preparations for cleansing and caring for blemished skin, e.g. synthetic detergents (solid or liquid), peeling or scrub preparations or peeling masks;
[0098] hair-removal preparations in chemical form (depilation), e.g. hair-removing powders, liquid hair-removing preparations, cream- or paste-form hair-removing preparations, hair-removing preparations in gel form or aerosol foams;
[0099] shaving preparations, e.g. shaving soap, foaming shaving creams, non-foaming shaving creams, foams and gels, preshave preparations for dry shaving, aftershaves or aftershave lotions;
[0100] fragrance preparations, e.g. fragrances (eau de Cologne, eau de toilette, eau de perfume, perfume de toilette, perfume), perfume oils or perfume creams;
[0101] dental care, denture-care and mouth-care preparations, e.g. toothpastes, gel toothpastes, tooth powders, mouthwash concentrates, anti-plaque mouthwashes, denture cleaners or denture fixatives;
[0102] cosmetic hair-treatment preparations, e.g. hair-washing preparations in the form of shampoos and conditioners, hair-care preparations, e.g. pre-treatment preparations, hair tonics, styling creams, styling gels, pomades, hair rinses, treatment packs, intensive hair treatments, hair-structuring preparations, e.g. hair-waving preparations for permanent waves (hot wave, mild wave, cold wave), hair-straightening preparations, liquid hairsetting preparations, hair foams, hairsprays, bleaching preparations, e.g. hydrogen peroxide solutions, lightening shampoos, bleaching creams, bleaching powders, bleaching pastes or oils, temporary, semi-permanent or permanent hair colourants, preparations containing self-oxidising dyes, or natural hair colourants, such as henna or camomile.
[0103] An antimicrobial soap has, for example, the following composition:
[0104] 0.01 to 5% by weight of a compound of formula (1) or (2),
[0105] 0.3 to 1% by weight titanium dioxide,
[0106] 1 to 10% by weight stearic acid,
[0107] ad 100% soap base, e.g. a sodium salt of tallow fatty acid or coconut fatty acid, or glycerol.
[0108] A shampoo has, for example, the following composition:
[0109] 0.01 to 5% by weight of a compound of formula (1) or (2),
[0110] 12.0% by weight sodium laureth-2-sulfate,
[0111] 4.0% by weight cocamidopropylbetaine,
[0112] 3.0% by weight NaCl and
[0113] water ad 100%.
[0114] A deodorant has, for example, the following composition:
[0115] 0.01 to 5% by weight of a compound of formula (1) or (2),
[0116] 60% by weight ethanol,
[0117] 0.3% by weight perfume oil, and
[0118] water ad 100%.
[0119] The invention relates also to an oral composition comprising
[0120] 0.01 to 15% by weight, based on the total weight of the composition, of a compound of formula (1) or (2), and orally tolerable adjuvants.
[0121] Example of an oral composition:
[0122] 10% by weight sorbitol,
[0123] 10% by weight glycerol,
[0124] 15% by weight ethanol,
[0125] 15% by weight propylene glycol,
[0126] 0.5% by weight sodium lauryl sulfate,
[0127] 0.25% by weight sodium methylcocyl taurate,
[0128] 0.25% by weight polyoxypropylene/polyoxyethylene block copolymer,
[0129] 0.10% by weight peppermint flavouring,
[0130] 0.1 to 0.5% by weight of a compound of formula (1) or (2) and
[0131] 48.6% by weight water.
[0132] The oral composition according to the invention may be, for example, in the form of a gel, a paste, a cream or an aqueous preparation (mouthwash).
[0133] The oral composition according to the invention may also comprise compounds that release fluoride ions which are effective against the formation of caries, for example inorganic fluoride salts, e.g. sodium, potassium, ammonium or calcium fluoride or organic fluoride salts, e.g. amine fluorides, which are known under the trade name Olafluor.
[0134] The tetrahydrocarbazoles of formula (1) or (2) used according to the invention are also suitable for treating, especially preserving, textile fibre materials. Such materials are undyed and dyed or printed fibre materials, e.g. of silk, wool, polyamide or polyurethanes, and especially cellulosic fibre materials of all kinds. Such fibre materials are, for example, natural cellulose fibres, such as cotton, linen, jute and hemp, as well as cellulose and regenerated cellulose. Preferred suitable textile fibre materials are made of cotton.
[0135] The tetrahydrocarbazoles according to the invention are suitable also for treating, especially imparting antimicrobial properties to or preserving, plastics, e.g. polyethylene, polypropylene, polyurethane, polyester, polyamide, polycarbonate, latex, etc. Fields of use therefore are, for example, floor coverings, plastics coatings, plastics container and packaging materials; kitchen and bathroom utensils (e.g. brushes, shower curtains, sponges, bathmats), latex, filter materials (air and water filters), plastics articles used in the field of medicine, e.g. dressing materials, syringes, catheters, etc., so-called “medical devices”, gloves and mattresses.
[0136] Paper, for example papers used for hygiene purposes, may also be provided with antimicrobial properties using the tetrahydrocarbazoles according to the invention.
[0137] It is also possible for nonwovens, e.g. nappies/diapers, sanitary towels, panty liners, and cloths for hygiene and household uses, to be provided with antimicrobial properties in accordance with the invention.
[0138] The tetrahydrocarbazoles of formula (1) or (2) are also used in washing and cleaning formulations, e.g. in liquid or powder washing agents or softeners.
[0139] The tetrahydrocarbazoles of formula (1) or (2) can be used especially in household and general-purpose cleaners for cleaning and disinfecting hard surfaces.
[0140] A cleaning preparation has, for example, the following composition:
3|
|
0.01 to 5%of a compound of formula (1) or (2),
3.0%octyl alcohol 4EO,
1.3%fatty alcohol C8-C10 polyglucoside,
3.0%isopropanol,
ad 100%water.
|
[0141] In addition to preserving cosmetic and household products, the preservation of technical products, the provision of technical products with antimicrobial properties and use as a biocide in technical processes are also possible, for example in paper treatment, especially in paper treatment liquors, print thickeners of starch or of cellulose derivatives, surface coatings and paints.
[0142] The tetrahydrocarbazoles of formula (1) or (2) according to the invention are suitable also for the antimicrobial treatment of wood and for the antimicrobial treatment of leather, the preservation of leather and the provision of leather with antimicrobial properties.
[0143] The compounds according to the invention are also suitable for the protection of cosmetic products and household products from microbial damage.
[0144] The tetrahydrocarbazoles according to the invention are suitable also as medicaments for the treatment of bacterial infections for oral, intravenous, subcutaneous or parenteral administration of the active ingredient.
[0145] The invention accordingly relates also to a medicament comprising a compound of formula (1) or (2) and therapeutically tolerable adjuvants, for the treatment of bacterial infections.
[0146] The following Examples illustrate the invention.
[0147] General Procedure for the Preparation of the Tetrahydrocarbazoles According to the Invention:
[0148] The appropriate (substituted) indole (compound (I)) (1 mmol) is dissolved with (substituted) maleimide (compound (IV) (1.2 mmol) and an aldehyde/ketone (compound (II) (2 mmol) in 1-butanol (1 ml).
[0149] There is then added to the mixture aqueous hydrochloric acid (2N; 50 μl; 0.1 mmol) or, in the case of piperidones, concentrated hydrochloric acid (32%; 220 μl; 1.1 mmol). The mixture is then heated at 95° C. for 3 hours.
[0150] After cooling to 25° C., the resulting tetrahydrocarbazole (compound (1)) is precipitated with n-hexane (3 ml).
[0151] After filtration, the filtrate is cooled to 5° C. in order to obtain further crystals. The combined crystals are washed with n-hexane/ethyl acetate and dried in vacuo.
[0152] All the compounds, that is to say the compounds of formulae (9) to (181), are characterised by LC-MS (for yields, see Table 1). Some of the compounds are analysed by NMR spectroscopy. The compounds are obtained in the form of mixtures of isomers (racemates or exo/endo isomers).
10-Bromo-3a,3b,4,5,6,7,8,8a,13,13b-decahydro-1H-cyclohepta[c]pyrrolo-[3,4-a]carbazole-1.3(2H)-dione (compound of formula (32)
[0153]
144
[0154] Yield: 72%
[0155] LC-MS: [M+H]+=386 (79Br)
[0156] NMR Data:
[0157] For reasons of clarity, the numbering used is not in accordance with IUPAC.
1454|
|
Assignmentd1H [ppm]d13C [ppm]
|
|
OC-1—176.5
HN-1approx. 11—
OC-3—180.4
HC-43.4044.1
HC-52.3237.6
H2C-61.8228.1
1.58
H2C-71.8830.4
1.28
H2C-81.7424.2
1.41
H2C-92.3927.3
1.81
H2C-101.7330.4
HC-113.1235.5
C-12—114.1
C-13—127.6
HC-147.48120.3
C-15—111.0
HC-167.16123.6
HC-177.31113.5
C18—135.7
HN-1911.11 —
C-20—128.8
HC-214.0941.6
|
3JH-21,H-4=7.9Hz;
3JH-4,H-5=5.1Hz
2,6-Dimethyl-3b,4,5,6,7,7a,12,12b-octahydrobenzo[c]pyrrolo[3.4 a]carbazole-1,3(2H,3aH)-dione (compound of formula (117))
[0158]
146
[0159] Yield: 79%
[0160] LC-MS: [M+H]+=322
[0161] NMR Data:
[0162] For reasons of clarity, the numbering used is not in accordance with IUPAC.
1475|
|
Isomer AIsomer B
Assignmentδ1H [ppm]δ13C [ppm]δ1H [ppm]δ13C [ppm]
|
OC-1—175.6a—175.9b
CH3—N-22.8124.42.7224.2
OC-3—178.6a—177.7b
HC-43.4443.93.4544.3
HC-52.3533.81.5840.8
H2C-61.9926.12.3329.2
1.731.83
H2C-71.8530.21.8035.1
1.510.96
H2C-81.6730.81.5831.7
H3C-90.7921.80.9622.5
H2C-101.8637.72.8440.0
0.960.91
HC-113.0233.62.5634.9
C-12—113.9—113.4
C-13—125.8—125.5
HC-147.46118.2c7.61119.9c
HC-156.93118.36.89118.3
HC-167.02d120.97.00d120.7
HC-177.34111.47.32111.4
C18—136.9—136.9
HN-1910.94—11.06—
C-20—126.6—127.6
HC-214.2143.84.2342.3
|
9-Bromo-6-methyl-3b,4,5,6,7,7a,12,12b-octahydrobenzo[c]pyrrolo-[3,4-a]carbazole-1,3(2H,3aH)-dione (compound of formula (70))
[0163]
148
[0164] Yield: 71%
[0165] LC-MS: [M+H]+=386 (79Br)
1496|
|
Isomer AIsomer B
Assignmentδ1H [ppm]δ13C [ppm]δ1H [ppm]δ13C [ppm]
|
OC-1—175.6a—175.9b
CH3—N-22.8124.42.7224.2
OC-3—178.6a—177.7b
HC-43.4443.93.4544.3
HC-52.3533.81.5840.8
H2C-61.9926.12.3329.2
1.731.83
H2C-71.8530.21.8035.1
1.510.96
H2C-81.6730.81.5831.7
H3C-90.7921.80.9622.5
H2C-101.8637.72.8440.0
0.960.91
HC-113.0233.62.5634.9
C-12—113.9—113.4
C-13—125.8—125.5
HC-147.46118.2c7.61119.9c
HC-156.93118.36.89118.3
HC-16 7.02d120.9 7.00d120.7
HC-177.34111.47.32111.4
C18—136.9—136.9
HN-1910.94 —11.06 —
C-20—126.6—127.6
HC-214.2143.84.2342.3
|
9-Bromo-6-methyl-3b,4,5,6,7,7a,12,12b-octahydrobenzo[c]pyrrolo-[3,4-a]carbazole-1,3(2H,3aH)-dione (compound of formula (70))
[0166]
150
[0167] Yield: 71%
[0168] LC-MS: [M+H]+386 (79Br)
[0169] NMR Data:
[0170] For reasons of clarity, the numbering used is not in accordance with IUPAC.
7|
|
Assignmentδ1H [ppm]δ13C [ppm]
|
|
OC-1—176.8
HN-111.06 —
OC-3—179.1
HC-43.43?
HC-51.5040.6
H2C-62.2629.1
1.75
H2C-71.7635.1
0.94
H2C-81.5631.7
H3C-90.9622.6
H2C-102.7539.7
0.85
HC-112.5734.7
C-12—113.2
C-13—127.3
HC-147.76121.8
C-15—110.8
HC-167.13123.1
HC-177.29113.3
C18—135.5
HN-1911.26 —
C-20—129.8
HC-214.1442.9
|
3JH-21,H-4=7.9Hz
3JH-4,H-5=4.1Hz
[0171] The remaining compounds listed in Table 1 can be prepared in analogous manner.
[0172] 4. Microbiological Test Results
[0173] Nutrient:
[0174] Casein/soybean flour peptone bouillon for the preparation of pre-cultures of the test bacteria and yeast.
[0175] Mycological slant agar for the pre-culture of moulds
[0176] Examples of Test Organisms:
8|
|
Staphylococcus hominis DMS 20328Staphylococcus epidermidis
Escherichia coli NCTC 8196ATCC 12228
Corynebacterium xerosis ATCC 373P. ovale ATCC 14521
Enterococcus hirae ATCC 10541Actinomyces viscosus DSM 43329
Micrococcus luteus ATCC 9341Porphyromonas gingivalis DSM 20709
Candida albicans ATCC 10259Selenomonas artemidis ATCC 43528
Staphylococcus aureus (methicillin-resistant) NCTCStreptococcus mutans ATOC 25175
11940Streptococcus sobrinus DSM 20742
Staphylococcus aureus (methicillin-resistant)Epidermophyton floccosum DSM 10709
NCTC 12493
Staphylococcus aureus (penicillin-resistant)Tr. mentagrophytes ATCC 9533
NCTC 10443Trichophyton rubrum DSM 4167
Staphylococcus aureus (rifampicin-resistant)Trichoderma longibrachiatum
NCTC 10703DSM 768
Propionibacterium acnes ATCC 25746Aspergillus niger ATCC 6175
|
[0177] Procedure:
[0178] The test substances are predissolved in dimethyl sulfoxide (DMSO) and tested in a dilution series of 1:2.
[0179] Bacteria and yeast are cultured overnight in CASO bouillon, the mould is cultured over-night on mycological slant agar, and washed off with 10 ml of 0.85% sodium chloride solution (+0.1% TritonX-100).
[0180] All the test organisms are adjusted to an organism count of 1-5×106 CFU/ml using 0.85% sodium chloride solution.
[0181] The test substances are pre-pipetted into microtitre plates in an amount of 8 μl per well.
[0182] Pre-diluted organism suspensions are diluted 1:100 in CASO bouillon (bacteria and yeast) or Sabouraud 2% glucose bouillon (mould) and are added in an amount of 192 μl per well to the test substances.
[0183] The test batches are incubated for 48 hours at 37° C. (bacteria and yeast) or for 5 days at 28° C. (mould).
[0184] After incubation, the growth is evaluated by reference to the turbidity of the test batches (optical density) at 620 nm in a microplate reader.
[0185] The minimum inhibitory concentration (MIC value) is the concentration of substance at which (compared with the growth of the control) an appreciable inhibition of growth (≦20% growth) of the test organisms is ascertained.
[0186] One microtitre plate is used for each test organism and substance concentration. All the substances are tested in duplicate.
[0187] The results are compiled in Table 2:
9TABLE 2
|
|
Minimum inhibitory concentrations (MIC) in ppm of the compounds synthesised
against Staphylococcus hominis DMS 20328 and Escherichia coli
CompoundMIC [ppm]MIC [ppm]CompoundMIC [ppm]MIC [ppm]
of formulaS. hominisE. coliof formulaS. hominisE. coli
|
9>36>3630>120>120
10>48>483115>120
11>120>120323.75>120
12>120>120333060
13>120>12034>120>120
14>120>12035>120>120
15>120>12036>120>120
16>120>12037>120>120
17>120>12038>120>120
18>120>12039>120>120
19>120>12040>120>120
20>120>12041>120>120
21>120>12042>120>120
22>120>12043>120>120
23>64>6444>120>120
24>120>12045>120>120
25>120>12046120120
2615>12047>120>120
2760>12048>120>120
28>120>12049>120>120
2915>12050>120>120
51>120>12080120>120
52>120>1208160120
53>120>1208230>120
54>120>12083>120>120
55>120>12084120>120
5630>12085>120>120
57>120>12086120>120
5830>1208715120
59>120>12088>120>120
60120>120897.5>120
613.75>12090>120>120
6215>12091>120>120
637.5>12092>120>120
64120>1209360>120
65120>12094>120>120
66>120>12095>120>120
67>120>12096>120>120
68>120>12097120>120
69120>12098>120>120
7015>12099120>120
7160>120100120>120
72120>120101>120>120
73160>12010260>120
7460>120103>120>120
7530>120104>120>120
76>120>120105>120>120
7715>1201063.75>120
7860>120107120>120
79120>120108>120>120
109>120>120138>120>120
110120>120139>120>120
11160>120140120>120
112>120>120141>120>120
113>120>120142>120>120
114>120>120143>120>120
11560>120144>120>120
116120>120145>120>120
117>120>120146>120>120
118>120>120147>120>120
119>120>120148>120>120
12030>120149120120
121>120>120150>120>120
122>120>120151>120>120
123>120120152120>120
124>120>120153>120>120
125>120>120154>120>120
126>120>120155>120>120
12760>120156>120>120
128>120>120157>120>120
129>120>120158>120>120
13015>1201597.5120
131>120120160120120
132>120>120161>120>120
133120>120162120>120
134120>120163>120>120
135>120>120164>120>120
136>120>120165120>120
137>120>120166>120>120
167>120>120
168>120>120
169>120>120
170>120>120
171>120>120
172>120>120
173>120>120
17430>120
175>120>120
176>120>120
177120120
178>120>120
179>120>120
180>120>120
181>120>120
|
[0188]
10
TABLE 3
|
|
|
Further minimum inhibitory concentrations (MIC) in ppm of selected compounds
|
(MIC values in ppm)
|
Compound of formula
|
Microorganism
61
63
70
87
89
106
|
|
Staphylococcus hominis
DSM
3.75
7.5
15
15
7.5
3.75
|
20328
|
Staphylococcus epidermidis
≦3.75
≦3.75
15
15
≦3.75
≦3.75
|
ATCC 12228
|
Corynebacterium xerosis
≦3.75
≦3.75
7.5
7.5
≦3.75
≦3.75
|
ATCC 373
|
Enterococcus hirae
7.5
7.5
60
30
>120
>120
|
ATCC 10541
|
Micrococcus luteus
ATCC 9341
≦3.75
≦3.75
15
15
≦3.75
≦3.75
|
Candida albicans
ATCC 10259
>120
>120
>120
>120
>120
>120
|
|
[0189]
11
TABLE 4
|
|
|
Minimum inhibitory concentrations (MIC) in ppm of compound
|
(32) against methicillin, penicillin-resistant Staphylococci and
|
other microorganisms
|
>(MIC values in ppm)
|
Compound of formula (32)
|
Microorganism
Microorganism
|
|
Staphylococus aureus
ATCC 9144
5.0 ppm
P. ovale
ATCC 14521
>10 ppm
|
Staphylococcus hominis
DSM 20328
5.0 ppm
Actinomyces viscosus
6.25 ppm
|
DSM 43329
|
Staphylococcus aureus
(methicillin-
5.0 ppm
Porphyromonas gingivalis
3.125 ppm
|
resistant) NCTC 11940
DSM 20709
|
Staphylococcus aureus
(methicillin-
5.0 ppm
Selenomonas artemidis
50.0 ppm
|
resistant) NCTC 12493
ATCC 43528
|
Staphylococcus aureus
(penicillin-
5.0 ppm
Streptococcus mutans
5.0 ppm
|
resistant) NCTC 10443
ATCC 25175
|
Staphylococcus aureus
(rifampicin-
5.0 ppm
Streptococcus sobrinus
6.25 ppm
|
resistant) NCTC 10703
DSM 20742
|
S. epidermidis
ATCC 12228
10 ppm
Candida albicans
ATCC
>10 ppm
|
10259
|
Corynebacterium xerosis
ATCC 373
5.0 ppm
Epidermophyton floccosum
5.0 ppm
|
DSM 10709
|
Micrococcus luteus
ATCC 9341
5.0 ppm
Tr. mentagrophytes ATCC
10 ppm
|
9533
|
Enterococcus hirae
ATCC 10541
>10 ppm
Trichophyton rubrum
DSM
10 ppm
|
4167
|
Propionibacterium acnes
ATCC
6.25 ppm
Trichoderma longibrachiatum
>10 ppm
|
25746
DSM 768
|
Aspergillus niger
ATCC
>10 ppm
|
6175
|
|
[0190]
12
TABLE 5
|
|
|
Minimum inhibitory conc ntrations (MIC) in ppm of
|
selected synthesised compounds against
|
selected test organisms
|
Compound
|
of
MIC [ppm]
MIC [ppm]
MIC [ppm]
MIC [ppm]
|
formula
S. hominis
E. coil
P. aeruginosa
A. niger
|
|
182
>120
>120
>120
>120
|
183
15
>120
>120
>120
|
184
>120
>120
>120
>120
|
185
>120
>120
>120
>120
|
186
>120
>120
120
>120
|
187
30
>120
60
>120
|
188
15
>120
>120
>120
|
189
15
120
>120
>120
|
190
>120
>120
>120
>120
|
191
7.5
>120
>120
120
|
192
7.5
>120
>120
>120
|
193
>120
60
>120
>120
|
194
7.5
>120
>120
>120
|
195
15
>120
>120
>120
|
196
7.5
>120
>120
>120
|
197
>120
>120
120
>120
|
198
>120
>120
>120
>120
|
199
120
>120
>120
>120
|
200
>120
>120
120
>120
|
201
>120
>120
60
>120
|
202
60
>120
120
>120
|
203
>120
>120
>120
>120
|
204
15
120
60
>120
|
205
7.5
>120
120
>120
|
206
7.5
>120
60
>120
|
207
>120
>120
120
>120
|
208
15
>120
>120
>120
|
209
30
>120
120
>120
|
210
120
>120
120
>120
|
211
>120
120
120
>120
|
212
120
>120
>120
>120
|
213
>120
>120
>120
>120
|
214
15
120
120
120
|
215
30
60
120
>120
|
216
15
120
120
120
|
217
<3.75
>120
>120
>120
|
218
15
>120
120
>120
|
219
>120
>120
>120
>120
|
220
15
>120
>120
>120
|
221
15
>120
60
>120
|
222
120
120
>120
>120
|
223
>120
>120
60
>120
|
224
>120
>120
120
>120
|
225
120
>120
120
>120
|
226
120
120
>120
>120
|
227
>120
>120
>120
>120
|
228
15
>120
>120
>120
|
229
>120
>120
>120
>120
|
230
120
>120
120
>120
|
231
120
>120
120
>120
|
232
>120
>120
>120
>120
|
233
15
>120
120
>120
|
234
>120
>120
120
>120
|
235
120
>120
>120
>120
|
236
>120
>120
120
>120
|
237
>120
>120
120
>120
|
238
>120
>120
>120
>120
|
239
120
120
120
>120
|
|
Claims
- 1. A compound of formula
- 2. A compound of formula (1) or (2) according to claim 1, wherein
R1 is hydrogen; C1-C20alkyl; C3-C12cycloalkyl; C2-C20alkenyl; C4-C12cycloalkenyl; C3-C20-alkynyl; C4-C12cycloalkynyl; phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C5alkyl, C3-C12cycloalkyl, C1-C5alkoxy, C3-C12cycloalkoxy, halogen, carboxy, C1-C7alkylcarbonyl, C1-C7alkoxycarbonyl, C3-C12cycloalkylcarbonyl, C3-C12-cycloalkoxycarbonyl, cyano, trifluoromethyl, pentafluoroethyl, amino, N,N-mono- or di-C1-C20alkylamino or by nitro, R2 is hydrogen; hydroxy; C1-C20alkyl; C3-C12cycloalkyl; C2-C20alkenyl; C4-C12cycloalkenyl; C3-C20alkynyl; C4-C12cycloalkynyl; C1-C20alkoxy; C2-C20alkenyloxy; C2-C20alkynyloxy; halogen; cyano; C1-C7alkylcarbonyl; nitro; trifluoromethyl; or pentafluoroethyl; R3 and R4 are each independently of the other hydrogen; or C1-C20alkyl; or R3 and R4 denote a C2-C20alkylene radical; a C2-C20alkenylene radical; a C4-C20alkynylene radical; or a C3-C20alkylene radical interrupted by —N(R6)—, it being possible for such bivalent radicals to be further substituted by one or more C1-C20alkyl, C3-CO12cycloalkyl, C2-C20-alkenyl, C4-C12cycloalkenyl, C3-C20alkynyl, C4-C12cycloalkynyl, C1-C7alkoxycarbonyl, or phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C5alkyl, C3-C12-cycloalkyl, C1-C5alkoxy, C3-C12cycloalkoxy, halogen, carboxy, C1-C7alkoxycarbonyl, C3-C12cycloalkoxycarbonyl, cyano, trifluoromethyl, pentafluoroethyl, amino, N,N-mono- or di-C1-C20alkylamino or by nitro; R5 is hydrogen; hydroxy; C1-C20alkyl; C1-C20alkoxy; C3-C12cycloalkyl; C2-C20alkenyl; C4-C12cycloalkenyl; C3-C20alkynyl; C4-C12cycloalkynyl; phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C5alkyl, C3-C12cycloalkyl, C1-C5alkoxy, C3-C12cycloalkoxy, halogen, carboxy, C1-C7alkoxycarbonyl, C3-C12cycloalkoxycarbonyl, cyano, trifluoromethyl, pentafluoroethyl, amino, N,N-mono- or di-C1-C20alkylamino or by nitro; R6 is hydrogen; C1-C20alkyl; C3-C12cycloalkyl; C2-C20alkenyl; C4-C12cycloalkenyl; C3-C20alkynyl; C4-C12cycloalkynyl; C1-C7alkoxycarbonyl; phenyl or phenyl-C1-C5alkyl each unsubstituted or substituted by C1-C5alkyl, C3-C12cycloalkyl, C1-C5alkoxy, C3-C12cycloalkoxy, halogen, carboxy, C1C7alkoxycarbonyl, C3-C12cycloalkoxycarbonyl, cyano, trifluoromethyl, pentafluoroethyl, amino, N,N-mono- or di-C1-C20alkylamino or by nitro; Q is —SO2—; —O—; or —(CO)—; X is —CH—; or —N—; m is from 1 to 3; and t is 0 or 1.
- 3. A compound according to claim 1 or claim 2, wherein
R1 is hydrogen; C1-C20alkyl; phenyl or phenyl-C1-C5alkyl.
- 4. A compound according to any one of claims 1 to 3, wherein
R1 is hydrogen; or C1-C5alkyl.
- 5. A compound according to any one of claims 1 to 4, wherein
R2 is hydrogen; C1-C20alkyl; C1-C20alkoxy; or halogen.
- 6. A compound according to any one of claims 1 to 5, wherein
R2 is hydrogen; C1-C5alkyl; C1-C5alkoxy; or halogen.
- 7. A compound according to any one of claims 1 to 6 that corresponds to formula
- 8. A compound according to claim 7, wherein
T1 is a —(CH2)2-12— radical and R6 is hydrogen; or C1-C5alkyl.
- 9. A compound according to claim 8, wherein
T1 is a —(CH2)3—, —(CH2l)4—, —(CH2)5—, or —(CH2)10— radical; and R6 is hydrogen; or C1-C5alkyl.
- 10. A compound according to any one of claims 1 to 9, wherein
R5 is hydrogen; C1-C20alkyl; phenyl or phenyl-C1-C5alkyl.
- 11. A compound according to any one of claims 1 to 10, wherein
R5 is hydrogen; C1-C5alkyl; or phenyl.
- 12. A compound according to any one of claims 1 to 11 of formula
- 13. A compound according to claim 12, wherein
R6′, R6″ and R6 are each independently of the others hydrogen; C1-C20alkyl; C1-C7-alkoxycarbonyl; phenyl; or phenyl-C1-C5alkyl.
- 14. A compound according to claim 13, wherein
R6′, R6″ and R6 are each independently of the others hydrogen; C1-C5alkyl; C1-C7-alkoxycarbonyl; phenyl or benzyl.
- 15. A compound according to any one of claims 1 to 14 that corresponds to formula
- 16. A process for the preparation of a compound of formula (1) or (2) according to claim 1, wherein an indole compound (I), a keto or aldehyde compound of formula (II) and a dienophile of formula (IV) or (V), respectively, are reacted in a suitable solvent using an acid catalyst at a temperature of from 50° C. to 140° C. to form a compound of formula (1) or (2), respectively, in accordance with the following scheme:
- 17. Use of a compound of formula (1) or (2) according to claim 1 in the antimicrobial treatment, deodorisation and disinfection of the skin, mucosa and hair.
- 18. Use according to claim 17, wherein the compound of formula (1) or (2) is used for disinfection and deodorisation.
- 19. Use of a compound of formula (1) or (2) according to claim 1 in the treatment of textile fibre materials.
- 20. Use according to claim 19, wherein the compound of formula (1) or (2) is used for preservation.
- 21. Use of a compound of formula (1) or (2) according to claim 1 in washing and cleaning formulations.
- 22. Use of a compound of formula (1) or (2) according to claim 1 in imparting antimicrobial properties to and preserving plastics, paper, nonwovens, wood or leather.
- 23. Use of a compound of formula (1) or (2) according to claim 1 in imparting antimicrobial properties to and preserving technical products, especially print thickeners of starch or of cellulose derivatives, surface coatings and paints.
- 24. Use of a compound of formula (1) or (2) according to claim 1 as a biocide in technical processes, especially in paper treatment.
- 25. A personal care preparation comprising
from 0.01 to 15% by weight, based on the total weight of the composition, of a compound of formula (1) or (2) according to claim 1 and cosmetically tolerable adjuvants.
- 26. An oral composition comprising from 0.01 to 15% by weight, based on the total weight of the composition, of a compound of formula (1) or (2) according to claim 1 and orally tolerable adjuvants.
- 27. A medicament comprising a compound of formula (1) or (2) according to claim 1 and therapeutically tolerable adjuvants, for the treatment of bacterial infections.
Priority Claims (2)
Number |
Date |
Country |
Kind |
008108441 |
Sep 2000 |
EP |
|
84301 |
May 2001 |
CH |
|
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/EP01/10479 |
9/11/2001 |
WO |
|